NASDAQ:CYTT Cyteir Therapeutics (CYTT) Stock Price, News & Analysis → The Presidential candidate you should REALLY be worried about (From Stansberry Research) (Ad) Free CYTT Stock Alerts $3.01 -0.01 (-0.33%) (As of 03/18/2024) Add Compare Share Share Today's Range$2.92▼$3.1950-Day Range$3.01▼$3.0152-Week Range$1.65▼$3.19Volume551,300 shsAverage VolumeN/AMarket Capitalization$108.36 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartEarningsFinancialsSEC FilingsSocial MediaStock AnalysisChartEarningsFinancialsSEC FilingsSocial Media Get Cyteir Therapeutics alerts: Email Address Ad Crypto 101 MediaShocking $16T Elon Musk Crypto LeakReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.Click here now to get your copy. About Cyteir TherapeuticsCyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the oncology therapeutics. Its lead product CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for combination therapy in solid tumors and hematologic malignancies. Cyteir Therapeutics, Inc. was incorporated in 2012 and is headquartered in Lexington, Massachusetts.Read More CYTT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CYTT Stock News HeadlinesNo headlines for this company have been tracked by MarketBeat.com Receive CYTT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cyteir Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today5/18/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CYTT CUSIPN/A CIK1662244 Webcyteir.com Phone857-285-4140FaxN/AEmployees46Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.94) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-46,060,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-24.88% Return on Assets-23.83% Debt Debt-to-Equity RatioN/A Current Ratio21.89 Quick Ratio21.89 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.13 per share Price / Book0.73Miscellaneous Outstanding Shares36,000,000Free Float30,814,000Market Cap$108.36 million OptionableN/A Beta0.08 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesMr. Joseph S. Zakrzewski (Age 62)Independent Investor & Independent Chairman of the Board Comp: $81.5kDr. Markus F. Renschler M.D. (Age 63)President, CEO & Director Comp: $718.62kDr. Kevin Mills Ph.D.Co-FounderMr. David G. Gaiero (Age 46)CFO & Treasurer Key CompetitorsAdicet BioNASDAQ:ACETRelmada TherapeuticsNASDAQ:RLMDConnect BiopharmaNASDAQ:CNTBPMV PharmaceuticalsNASDAQ:PMVPCitius PharmaceuticalsNASDAQ:CTXRView All Competitors CYTT Stock Analysis - Frequently Asked Questions How have CYTT shares performed in 2024? Cyteir Therapeutics' stock was trading at $3.01 on January 1st, 2024. Since then, CYTT shares have increased by 0.0% and is now trading at $3.01. View the best growth stocks for 2024 here. How do I buy shares of Cyteir Therapeutics? Shares of CYTT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CYTT) was last updated on 5/18/2024 by MarketBeat.com Staff From Our PartnersShocking $16T Elon Musk Crypto LeakCrypto 101 MediaA letter is coming from the "Bureau of the Fiscal Service".Stansberry ResearchHe called Apple at $1.49 and now he says: “Buy these 6 AI stocks.”InvestorPlaceCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingMake this ONE trade on Tuesday at 2 p.m. EST!Monument Traders Alliance[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressHe Is Giving Away BitcoinCrypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cyteir Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.